Pan American Health Organization

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on: 
Thursday, March 21, 2024
Control, EST, Congress, Lyme disease, CEPI, Coalition, Saint-Herblain, Pan American Health Organization, Walter, PAHO, International Vaccine Institute, Chikungunya, Epidemic, Drug, IVI, CDC, Process, VLA, Euronext Paris, Market access, ACIP, The 24th

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points: 
  • The Company will have a display in the exhibit area of the congress at booth #433.
  • There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
  • Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
  • Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
Wednesday, March 6, 2024
International, Cervical cancer, Research, Global Financing Facility, SUCCESS, World Bank, PAHO, International development, World Health Organization, Gavi, Pan American Health Organization, Molina Healthcare, UNICEF, HPV, Jhpiego, Bill, WHO, Vaccine

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Kamada Issues 2024 CEO Letter to Shareholders

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, KMDA, CMV, Hospital, Division, EMA, CSL Behring, Letter, Physician, Critical care, FDA, Technology transfer, Food, Growth, FEV1, AAT, Immunoglobulin G, Safety, University, European Medicines Agency, Food and Drug Administration, Pan American Health Organization, Patient, Plasma, Research, Partnership, Pharmaceutical industry

The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.

Key Points: 
  • The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
  • Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year.
  • These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk.
  • On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize.

Dr. Ben Carson & Dr. Michael Beckwith Pray for the Nation on Super Tuesday, Hosted by Soaak Technologies

Retrieved on: 
Wednesday, March 6, 2024
Theta, Nation, Love, Freedom, EMDR, Housing, Hope, Death, Super, Health, Safety, Thermography, Brain mapping, Pediatric neurosurgery, God the Father, Agape International Spiritual Center, Metabolic typing, Pan American Health Organization, Patient, Neurosurgery, Low-level laser therapy, Former, Consciousness, Johns Hopkins Hospital, Beauty, Medical device

TULSA, Okla., March 6, 2024 /PRNewswire/ -- Soaak Technologies, Inc. (https://www.soaak.com/), a health-tech company known for their clinically proven sound frequency composition therapies, welcomed Dr. Ben Carson and Dr. Michael Beckwith for Super Tuesday 2024 to visit the new state of the art Soaak Clinic located in Tulsa Oklahoma, noting the importance of advancements in technology in health and wellness being a matter that should have extreme attention on both sides of the political aisle heading into the 2024 elections. Dr. Ben Carson being the Chief of Pediatric Neurosurgery at Johns Hopkins Hospital, Former United States Secretary of Housing and Urban Development, and Former Presidential Candidate (2016), and Dr. Michael Beckwith, author, and founder and spiritual director of the Agape International Spiritual Center, along with Soaak Executives, led a prayer focused on healing and uniting the nation. The visit comes on the heels of the U.S. Air Force Awarding Soaak Technologies a second contract to Enhance Airmen's Performance, using their proprietary Sound Frequency Compositions.

Key Points: 
  • "We are honored that Dr. Ben Carson and Dr. Michael Beckwith joined us at our Soaak Clinic to bear witness to how we are affecting change on such a notable day for America.
  • To kickstart the Super Tuesday event, Soaak Executive Chairman Henry Penix, alongside Dr. Ben Carson and Dr. Michael Beckwith, led a prayer for the Nation.
  • Dr. Ben Carson began the prayer by saying, "Heavenly Father, we gather here in gratitude for the peace, safety, and freedom we enjoy.
  • "I was honored to meet Dr. Carson for the first time and join him in prayer for our Nation on this Super Tuesday," stated Dr. Michael Beckwith.

The Ashley Lashley Foundation Launches Call for Applications for 2024 HEY Campaign Ambassadorship Programme and Regional Focal Points

Retrieved on: 
Wednesday, February 14, 2024
Clara Lionel Foundation, Ambassador, Health, Climate change, Pan American Health Organization, UNICEF, HEY

BRIDGETOWN, Barbados, Feb. 14, 2024 /PRNewswire/ -- The Ashley Lashley Foundation proudly launches the application process for the 2024 HEY Campaign Ambassadorship Programme and Regional Focal Points (RFPs), signaling an exciting new phase for the 4th edition of the Healthy and Environment-friendly Youth (HEY) Campaign.

Key Points: 
  • BRIDGETOWN, Barbados, Feb. 14, 2024 /PRNewswire/ -- The Ashley Lashley Foundation proudly launches the application process for the 2024 HEY Campaign Ambassadorship Programme and Regional Focal Points (RFPs), signaling an exciting new phase for the 4th edition of the Healthy and Environment-friendly Youth (HEY) Campaign.
  • The HEY Ambassadorship and Country Network Programme, central to the campaign's mission, will bring together diverse groups of young people to collaborate under country networks, advocating for climate action and health policies.
  • Meanwhile, Regional Focal Points (RFPs) will play a crucial role in overseeing and guiding Ambassadors within their respective regions, ensuring effective advocacy efforts.
  • The application deadline for RFPs is March 7th 2024, and for Ambassadors, it's March 15th 2024.

Healixa Inc. Announces Regional Distribution Agreement for its Eternal Spring™ Deposition Water Harvester™ Technology

Retrieved on: 
Tuesday, February 6, 2024
Hygiene, Pan American Health Organization, Environment, Water, British Virgin Islands, Region, Sanitation, OTC, World Health Organization, ES1

Huntington, NY, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Healixa Inc. (OTC: EMOR) (“Healixa” or the “Company”)  is proud to announce that the Company has entered into a Regional Distribution Agreement with Caribbean Resource Solutions LLC to enable sales and distribution for its Eternal Spring™ Deposition Water Harvester™ technology in 18 countries and territories within the Caribbean Basin.

Key Points: 
  • Huntington, NY, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Healixa Inc. (OTC: EMOR) (“Healixa” or the “Company”)  is proud to announce that the Company has entered into a Regional Distribution Agreement with Caribbean Resource Solutions LLC to enable sales and distribution for its Eternal Spring™ Deposition Water Harvester™ technology in 18 countries and territories within the Caribbean Basin.
  • This Regional Distribution Agreement is anticipated to begin generating sales and distribution for the Company’s Eternal Spring™ Deposition Water Harvester™ technology in Aruba, Anguilla, Antigua and Barbuda, Barbados, Bonaire, the British Virgin Islands, Curaçao, Grenada, Guadeloupe, Martinique, Saba, Saint Barthélemy, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Sint Eustatius, Sint Maarten, and Trinidad and Tobago.
  • With far higher absolute humidity in all 18 aforementioned countries and territories, the Company anticipates that its Eternal Spring™ Deposition Water Harvester™ technology will outperform expectations in the Caribbean region.
  • "This Caribbean market will undoubtedly become a major revenue center for the Company’s Eternal Spring™ Deposition Water Harvester™ technology,” stated Ian Parker, CEO of Healixa.

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

Retrieved on: 
Friday, November 10, 2023
VLA, CEPI, Webcast, LMIC, Epidemic, Disease, Euronext Paris, Health Canada, Viral, Research, Low, Saint-Herblain, Climate change, Licensure, Safety, Food, PRV, Advisory Committee, European Medicines Agency, Ageing, Valneva SE, Risk, Pan American Health Organization, Priority review, Fatigue, EMA, Patient, Climate, FDA, Vaccine, Death, Notifiable disease, ACIP, Coalition, Priority, Trial of the century, Partnership, Arthralgia, R, PAHO, Temperature, Travel, Pharmaceutical industry, Lancet, CHIKV, Instituto Butantan, Chikungunya

Continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies.

Key Points: 
  • Continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies.
  • As sponsor of the first chikungunya vaccine approved in the U.S., Valneva has received a Priority Review Voucher (PRV) from the FDA, which it intends to monetize to help finance its research and development (R&D) programs.
  • With this U.S. approval, IXCHIQ® becomes the world’s first licensed chikungunya vaccine available to address this unmet medical need and the third vaccine Valneva1 has brought from early R&D to approval.
  • Initial safety data from this trial were included in the submission to the European Medicines Agency (EMA) in October 202313.

The Bahamas’ National Health Insurance Authority and eClinicalWorks Report Significant Progress with Electronic Health Records

Retrieved on: 
Thursday, December 14, 2023
Technology, Diabetes, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Health, Data Management, Oncology, EHR, National Health Insurance Authority, Primary care, Pan American Health Organization, Patient, Electronic health record, Death, Notifiable disease, Population health, PAHO, National health insurance, NCD, Cancer, Nursing, Pharmaceutical industry, The Bahamas

The National Health Insurance Authority (NHIA) has seen significant progress since the launch of its Electronic Health Record (EHR) system.

Key Points: 
  • The National Health Insurance Authority (NHIA) has seen significant progress since the launch of its Electronic Health Record (EHR) system.
  • The NHIA has partnered with eClinicalWorks , the largest ambulatory cloud EHR and provider of digital healthcare solutions to transform healthcare delivery, and has adopted population health tools that help to analyze population health.
  • With over 150,000 residents enrolled in the NHI Bahamas program, the EHR system aims to enhance patient care, improve operational efficiency, and drive positive health outcomes.
  • “By implementing eClinicalWorks EHR and population health tools, the NHIA is better equipped to track compliance data and improve long-term patient care.”

AHF Praises Colombia's Stand for Accessible HIV Treatment

Retrieved on: 
Friday, October 6, 2023
Infectious Diseases, LGBTQ+, Public Policy, Government, Biotechnology, AIDS, Pharmaceutical, Consumer, Health, Other Policy Issues, ViiV Healthcare, Pan American Health Organization, Lopinavir/ritonavir, Drug resistance, AIDS Healthcare Foundation, AHF, Travel, HIV, Medicine, Laboratory, Abbott Laboratories, Abbott, Refugee, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) supports and applauds the Colombian government’s decision to utilize a compulsory license to import cheaper generic versions of ViiV Healthcare’s HIV treatment dolutegravir.

Key Points: 
  • AIDS Healthcare Foundation (AHF) supports and applauds the Colombian government’s decision to utilize a compulsory license to import cheaper generic versions of ViiV Healthcare’s HIV treatment dolutegravir.
  • The country spends 50 times more on the brand-name drug than the Pan American Health Organization pays for a generic version.
  • AHF opened a clinic in Cúcuta, Colombia , in September 2018 at a critical border crossing with Venezuela to support people living with HIV among the thousands of refugees fleeing the country.
  • Without reliable access to antiretroviral therapy, Venezuelans living with HIV risk dying or developing drug resistance due to treatment interruptions in their home country.

Global Sustained Release Excipients Research Report 2023: Embracing the Future of Drug Delivery - The Growing Demand for Sustained-Release Excipients to 2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Medical Supplies, Health, Chemicals, Plastics, Medical Devices, Manufacturing, Pharmaceutical, Biotechnology, Sugar, Polymer, Wurster, Pan American Health Organization, Acquisition, Tuberculosis, Inflammation, Prevalence, API, Arena Pharmaceuticals, Cancer, Diabetes, WHO, World Health Organization, Gelatin, Growth, Mineral, Excipient, Chitosan, Pfizer, Pharmaceutical industry

The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In a rapidly evolving pharmaceutical landscape, the quest for more advanced drug delivery mechanisms is paramount.
  • Their role becomes increasingly essential as the global population grapples with both acute and chronic diseases.
  • The countries covered in the sustained-release excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.